Skip to main content
. Author manuscript; available in PMC: 2014 Mar 3.
Published in final edited form as: J Neurochem. 2008 Jul 1;106(1):313–319. doi: 10.1111/j.1471-4159.2008.05390.x

Fig. 1.

Fig. 1

(a) Size-exclusion chromatography of serum radioactivity 10 min after i.v. injection of 125I-IL15. The control involved collection of blood into a test tube containing the 125I-IL15 to assess the extent of ex vivo degradation. In both samples, intact 125I-IL15 represented more than 95% of the total radioactivity, the rest being free 125I. (b) Size-exclusion chromatography of radioactivity in brain homogenate 10 min after i.v. injection of 125I-IL15. The control involved homogenization of an untreated brain in a homogenizer containing 125I-IL15. Intact 125I-IL15 accounted for 95% of the total radioactivity in these samples. IL, interleukin.